This article was originally published in The Gray Sheet
Shipments of the Discovery II single-sensor pacemaker will begin in early April following FDA approval via PMA supplement, annouced March 16. The device's "expanded diagnostic capability will complement our very successful blended sensor product, the Pulsar Max pacemaker," Guidant notes
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.